Chemocentryx Drug Patent Portfolio
Chemocentryx owns 1 orange book drug protected by 4 US patents Given below is the list of Chemocentryx's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11603356 | Amorphous form of a complement component C5a receptor | 29 May, 2041 | Active |
| US11951214 | Capsule formulations | 27 Nov, 2039 | Active |
| US8445515 | C5aR antagonists | 03 Feb, 2031 | Active |
| US8906938 | C5aR antagonists | 21 Dec, 2029 | Active |
Latest Legal Activities on Chemocentryx's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Chemocentryx.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 16 Apr, 2024 | US11951214 |
|
Email Notification
Critical
| 16 Apr, 2024 | US11951214 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 12 Apr, 2024 | US8906938 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 12 Apr, 2024 | US8445515 |
|
Email Notification
Critical
| 12 Apr, 2024 | US8906938 |
|
Email Notification
Critical
| 12 Apr, 2024 | US8445515 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 09 Apr, 2024 | US11951214 |
| Recordation of Patent eGrant | 09 Apr, 2024 | US11951214 |
|
Email Notification
Critical
| 09 Apr, 2024 | US11951214 |
| Mail Patent eGrant Notification | 09 Apr, 2024 | US11951214 |
|
Recordation of Patent Grant Mailed
Critical
| 09 Apr, 2024 | US11951214 |
| Patent eGrant Notification | 09 Apr, 2024 | US11951214 |
|
Email Notification
Critical
| 03 Apr, 2024 | US11603356 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 03 Apr, 2024 | US11603356 |
|
Email Notification
Critical
| 21 Mar, 2024 | US11951214 |
Chemocentryx's Family Patents
Chemocentryx drugs have patent protection in a total of 33 countries. It's US patent count contributes only to 24.7% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Chemocentryx Drug List
Given below is the complete list of Chemocentryx's drugs and the patents protecting them.
1. Tavneos
Tavneos is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11603356 | Amorphous form of a complement component C5a receptor |
29 May, 2041
(16 years from now)
| Active |
| US11951214 | Capsule formulations |
27 Nov, 2039
(15 years from now)
| Active |
| US8445515 | C5aR antagonists |
03 Feb, 2031
(6 years from now)
| Active |
| US8906938 | C5aR antagonists |
21 Dec, 2029
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tavneos's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List